Skip to main content
Equibles
ATYR logo

ATYR · aTYR PHARMA INC

Track ATYR — free

Use ATYR with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research ATYR.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$0.28 -0.01 (-1.81%) At close · Oct 5
Rebalance outlook locked
Market Cap
$31.18M
Shares
98.09M
Volume · Oct 5 1.81M Avg daily vol (3M) 3.26M

Price & Indicators

Drag to pan · scroll to zoom
Indicators
Price
Panels
Event markers
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$0.29 Open$0.29 Day$0.28–0.30 52W close$0.29–1.06 Avg vol 30d5.7M Short int10.7M · 10.9% float · 11.9d Short vol41% Last earningsMar 13, 2025 DataJan 2020–Oct 2026 Filing10-Q · Aug 7

Up next

Latest filing: 10-Q
filed Aug 7, 2026
Q4 2024 earnings call transcript
call held Mar 13, 2025

Metrics snapshot

Useful current figures from the complete screener profile.

Revenue (TTM)
$190,000
Trailing 12 months
Net income (TTM)
−$60.81M
Trailing 12 months
Revenue growth YoY
-19.1%
Year over year
Operating margin
-40,856.3%
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
-175.8%
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+8.8%
Year over year · more shares
Price change (1Y)
-59.5%
Trailing year
Short interest
10.9%
Latest settlement · 11.9 days to cover
View all 115 metrics

Equibles Rating

blended score · not investment advice
Overall
Strong Sell
SellHoldBuy
Technical Strong Sell Momentum Very Weak Sentiment Bearish Fundamentals Poor Quant / Vol Very High
Market backdrop VIX 15.3 · calm Equity put/call 0.58
Technical
price trend
Strong Sell
50 / 200-day cross No cross
Price vs 200-day avg −56%
below
Price vs 50-day avg −37%
below
RSI (14) 25
oversold
MACD trend Negative
52-week position 0%
near low
Volume (OBV) Confirms
volume backs price
Momentum
relative strength
Very Weak
1-month return −43%
trailing
6-month return −65%
trailing
YTD return −63%
this year
Relative strength −77%
vs S&P · 6-mo
Sentiment
smart money
Bearish
Trend (MA cross) No cross
50d $0 › 200d $1 — 200d above 50d
Institutional flow Distributing
-19% holders QoQ · +16 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Rising
10.88% of float · ▲ +15.0% MoM · 11.9 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
92 holders — mid 3-yr range
Squeeze score 74
high risk · 0–100
Fundamentals
Poor
Revenue growth −19%
Y/Y
EPS growth +7%
Y/Y
Free cash flow $-62.1M
Quant / Vol
risk profile
Very High
Volatility 109%
annualized · 1-yr
Max drawdown −73%
past year
ATR 11.6%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Technicals

trend & momentum for long-term holders Strong Sell
4 · 3 · 0
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
−56% Bearish
Price vs 50-day avg
−37% Bearish
RSI (14)
25 Neutral
MACD trend
Negative Bearish
52-week position
0% Bearish
Volume (OBV)
Confirms Neutral
Market signals — smart money & positioning
Bearish · 2 of 6
Trend (MA cross) No cross
50d $0 › 200d $1 — 200d above 50d
Institutional flow Distributing
-19% holders QoQ · +16 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Rising
10.88% of float · ▲ +15.0% MoM · 11.9 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
92 holders — mid 3-yr range
Price context
position in its 52-week range
Range low $0 Now $0 · 0% Range high $1
vs 200-day avg -56% vs 50-day avg -37%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.

Versus peers

Biotechnology — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
ATYR
aTYR PHARMA INC
this stock
$31.18M -63.3% -19.1% — 10.9%
VRTX
Vertex Pharmaceuticals Inc / Ma
 $133.37B +11.3% +46.2% 30.7 1.9%
REGN
Regeneron Pharmaceuticals, Inc.
 $81.13B -4.8% +20.8% 19.5 2.5%
MRNA
Moderna, Inc.
 $79.40B +544.3% +4.3% — 8.2%
CSLLY
Csl Ltd
 $61.25B — — — 0.0%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Reducing
Holders
92
% held
40.4%
Net QoQ
-17.3M sh
Top holder
FEDERATED HERMES, INC.
Held Float
View
Held by Funds
Fund positions
43
View
Short & Settlement
Short Interest Rising
Shares short
10.7M
Days to cover
11.9d
Change
+1.4M sh
View
Short Volume
Short vol %
41%
As of
Oct 5, 2026
Short Total
View
Fails to Deliver
FTD shares
327
Value
$157
As of
Sep 9, 2026
View
Off-Exchange
Off-exchange %
57.1%
Week of
Aug 31, 2026
Off-exch Lit
View
Financials
Financials
Revenue (FY)
$190.0K
Net income (FY)
$-74.1M
EPS diluted
$-0.80
View
Filings
SEC Filings
Latest
8-K
Filed
Sep 24, 2026
This year
17
View
Earnings & Events
Webcasts
Last webcast
Jun 4, 2026
View

Performance

5D 20D 120D MTD YTD
ATYR -5.8% -43.0% -64.5% -5.2% -63.3%
SPY -0.2% -0.5% +12.2% +0.9% +12.9%
vs SPY -5.6% -42.6% -76.7% -6.1% -76.2%
Key facts CIK 1339970 CUSIP 002120202 13F (30d) 1 filings 1 filers Visit website Investor relations